BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus

[1]  S. Jackson,et al.  BAFF inhibition in SLE—Is tolerance restored? , 2019, Immunological reviews.

[2]  L. Willen,et al.  Inhibition of Membrane-Bound BAFF by the Anti-BAFF Antibody Belimumab , 2018, Front. Immunol..

[3]  Joseph H. Marcus,et al.  Overexpression of the Cytokine BAFF and Autoimmunity Risk , 2017, The New England journal of medicine.

[4]  Aleksander Lenert,et al.  Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date , 2017, Drug design, development and therapy.

[5]  Y. Heo,et al.  Molecular Basis for the Neutralization of Tumor Necrosis Factor α by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases , 2017, International journal of molecular sciences.

[6]  S. Ryu,et al.  Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy , 2016, Nature Communications.

[7]  S. Dewire,et al.  Unexpected Potency Differences between B-Cell–Activating Factor (BAFF) Antagonist Antibodies against Various Forms of BAFF: Trimer, 60-Mer, and Membrane-Bound , 2016, The Journal of Pharmacology and Experimental Therapeutics.

[8]  R. Scarpa,et al.  Progress in understanding and utilizing TNF-α inhibition for the treatment of psoriatic arthritis , 2016, Expert review of clinical immunology.

[9]  Seng-Lai Tan,et al.  Stoichiometry of Heteromeric BAFF and APRIL Cytokines Dictates Their Receptor Binding and Signaling Properties* , 2015, The Journal of Biological Chemistry.

[10]  K. Kikly,et al.  Generation and characterization of tabalumab, a human monoclonal antibody that neutralizes both soluble and membrane-bound B-cell activating factor , 2014, Journal of inflammation research.

[11]  P. Schneider,et al.  The BAFF/APRIL system in SLE pathogenesis , 2014, Nature Reviews Rheumatology.

[12]  W. Stohl.  Future prospects in biologic therapy for systemic lupus erythematosus , 2013, Nature Reviews Rheumatology.

[13]  Ya-jun Guo,et al.  Comparison of the Inhibition Mechanisms of Adalimumab and Infliximab in Treating Tumor Necrosis Factor α-Associated Diseases from a Molecular View* , 2013, The Journal of Biological Chemistry.

[14]  Z. Rao,et al.  Structural Basis for Treating Tumor Necrosis Factor α (TNFα)-associated Diseases with the Therapeutic Antibody Infliximab* , 2013, The Journal of Biological Chemistry.

[15]  K. Latinis,et al.  Effect of Belimumab on Vaccine Antigen Antibodies to Influenza, Pneumococcal, and Tetanus Vaccines in Patients with Systemic Lupus Erythematosus in the BLISS-76 Trial , 2012, The Journal of Rheumatology.

[16]  K. Latinis,et al.  Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. , 2012, Arthritis and rheumatism.

[17]  C. Putterman,et al.  Dispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice. , 2012, Arthritis and rheumatism.

[18]  A. Rajeswaran,et al.  Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial , 2012, Arthritis Research & Therapy.

[19]  D. Hilbert,et al.  The discovery and development of belimumab: the anti-BLyS–lupus connection , 2012, Nature Biotechnology.

[20]  M. Petri,et al.  Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial , 2011, The Lancet.

[21]  Randy J. Read,et al.  Acta Crystallographica Section D Biological , 2003 .

[22]  P. Schneider,et al.  Cracking the BAFF code , 2009, Nature Reviews Immunology.

[23]  Meit A. Bjorndahl,et al.  Articles on similar topics can be found in the following Blood collections , 2006 .

[24]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[25]  Jianping Yin,et al.  Synthetic anti-BR3 antibodies that mimic BAFF binding and target both human and murine B cells. , 2006, Blood.

[26]  Fang Qian,et al.  Formation of virus-like clusters is an intrinsic property of the tumor necrosis factor family member BAFF (B cell activating factor). , 2006, Biochemistry.

[27]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[28]  T. Phan,et al.  Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. , 2004, Immunity.

[29]  J. Cyster,et al.  Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. , 2004, Immunity.

[30]  V. Roschke,et al.  Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. , 2003, Arthritis and rheumatism.

[31]  R. Kelley,et al.  BAFF/BLyS receptor 3 comprises a minimal TNF receptor-like module that encodes a highly focused ligand-binding site. , 2003, Biochemistry.

[32]  Xia Hong,et al.  Ligand–receptor binding revealed by the TNF family member TALL-1 , 2003, Nature.

[33]  S. Paik,et al.  Crystal structure of the BAFF–BAFF-R complex and its implications for receptor activation , 2003, Nature Structural Biology.

[34]  D. Seshasayee,et al.  BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. , 2002, Immunity.

[35]  Eddy Arnold,et al.  Structural basis of BLyS receptor recognition , 2002, Nature Structural Biology.

[36]  H. Shu,et al.  Crystal Structure of sTALL-1 Reveals a Virus-like Assembly of TNF Family Ligands , 2002, Cell.

[37]  J. Tschopp,et al.  BAFF-R, a Newly Identified TNF Receptor That Specifically Interacts with BAFF , 2001, Science.

[38]  S. Dillon,et al.  TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. , 2001, Immunity.

[39]  V. Roschke,et al.  Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. , 2001, Arthritis and rheumatism.

[40]  G. Alarcón,et al.  Cutting Edge: A Role for B Lymphocyte Stimulator in Systemic Lupus Erythematosus1 , 2001, The Journal of Immunology.

[41]  V. Dixit,et al.  Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity , 2000, Nature Immunology.

[42]  Don Foster,et al.  TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease , 2000, Nature.

[43]  D. Lacey,et al.  Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[44]  J. Tschopp,et al.  Mice Transgenic for Baff Develop Lymphocytic Disorders along with Autoimmune Manifestations , 1999, The Journal of experimental medicine.

[45]  Amy S Orr,et al.  BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. , 1999, Science.

[46]  J. Tschopp,et al.  BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth , 1999, The Journal of experimental medicine.

[47]  C. Ware.  Protein therapeutics targeted at the TNF superfamily. , 2013, Advances in pharmacology.

[48]  D. Greaves,et al.  deltaBAFF, a splice isoform of BAFF, opposes full-length BAFF activity in vivo in transgenic mouse models. , 2005, Journal of immunology.

[49]  G. Nagy,et al.  T- and B-cell abnormalities in systemic lupus erythematosus. , 2005, Critical reviews in immunology.

[50]  J. Tschopp,et al.  Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. , 2002, The Journal of clinical investigation.